Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVABN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Anywaine Z et al.
Safety, immunogenicity and risk–benefit analysis of rVSV- G-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions
Bache Emmanuel Bache, Martin P Grobusch & Selidji Todagbe Agnandji
Ebola virus vaccine receives prequalification